Know2eat

Boswellic acid isolate (AKBA)

Isolated Compounds

What boswellic acid isolate (akba) may help with

Ranked by how strong the human evidence is — best supported first.

Best supportedJoint comfortLimited evidence· 3 sources

Then, in order

About Boswellic acid isolate (AKBA)

A purified triterpene from Boswellia serrata resin, concentrated far above its natural abundance in the gum. Standard boswellia extracts contain a few percent AKBA; isolates are standardised to 20–30%.

AKBA is the fraction of frankincense resin with the most specific mechanism: it inhibits 5-lipoxygenase, an enzyme in the leukotriene pathway that ordinary anti-inflammatory drugs do not touch. That distinctiveness is why it has been pursued. The clinical evidence is a set of small trials in knee osteoarthritis, mostly from Indian research groups and mostly funded by the companies that patented the enriched extracts, reporting improvements in pain and function within days to weeks. Independent replication outside those sponsor relationships is limited. The isolate is also a genuinely different product from the whole-resin boswellia extract that has been used traditionally, and evidence for one is not evidence for the other.

Sold as
Capsule (standardised enriched extract), Tablet, Combination with curcumin
Standardised to
Percentage AKBA — commonly 20% or 30% in patented enriched extracts, versus 1–3% in ordinary boswellia extract — a product without this marker may not resemble what was studied.
Also known as
AKBA, 3-O-acetyl-11-keto-β-boswellic acid, 5-Loxin, Aflapin

Regulation: Sold as a dietary supplement in the US with no pre-market efficacy review. Patented enriched extracts are proprietary preparations, and generic products labelled "boswellia" are usually not equivalent.

What the research used

The amounts, forms and durations published trials of Boswellic acid isolate (AKBA) actually administered.

These are the amounts published trials administered — not a recommendation, and not a dose to copy. Trial participants were screened, supervised and given a characterised preparation. What is in a retail bottle is frequently not what was studied, and the amount that suits one person is not general advice.

  • Studied for Knee osteoarthritis

    100–250 mg

    Limited

    Enriched extract capsule, daily · 20–30% AKBA · 30–90 days

    Doses from the trials of the patented enriched extracts. Those trials are small, and the sponsor developed and sells the material, so the effect sizes should be read as optimistic.

  • Studied for Traditional whole-resin extract

    300–1200 mg

    Limited

    Boswellia serrata extract, divided doses · 60–65% total boswellic acids

    The older dosing used for unenriched extract, included here because products are often confused. It delivers far less AKBA than an isolate at a fraction of the milligrams.

This is general information about food, not medical advice. It cannot diagnose, treat or replace guidance from a clinician who knows your history.

When it was taken

Each window says whether a trial compared it against an alternative, or whether it is convention and pharmacology. Most timing advice is the second kind.

Each timing below was actually compared against an alternative in a trial, which is unusual.

  • With food

    Limited

    Boswellic acids are lipophilic and absorption improves with a high-fat meal in pharmacokinetic studies, with AKBA in particular showing very poor uptake fasted.

    Timing was tested. A trial compared this window against another and reported a difference.

The evidence in depth

Best supported: Limited

What each association actually rests on, and the papers behind it. A rating describes the state of the research, not how promising the supplement sounds. How we rate evidence.

Joint comfort

Joint Health
Limited evidence

Small randomised trials of AKBA-enriched extracts report reduced knee osteoarthritis pain and improved function, sometimes within a week. The trials are small, short, and conducted by or with the companies that own the extracts; independent confirmation is limited.

What may be going on: AKBA inhibits 5-lipoxygenase, reducing leukotriene synthesis, and has been reported to inhibit cathepsin G and matrix metalloproteinase-3 in laboratory systems.

Limited evidence. Early human work, or mostly lab and animal research.

View the 3 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Inflammatory markers

Inflammation
Not enough evidence

Reductions in matrix metalloproteinase and inflammatory markers have been reported in small trials alongside symptom outcomes. The data are too limited to characterise an effect.

Not enough evidence. Not enough human research to say anything useful yet.

View the 3 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Respiratory function

Respiratory Health
Not enough evidence

The leukotriene mechanism has prompted interest in asthma, but the human trials are very old, small and methodologically weak. There is not enough evidence to say anything.

Not enough evidence. Not enough human research to say anything useful yet.

View the 3 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Things to know

Interactions, contraindications and dose limits, most serious first. Concentrated extracts interact with medication in ways the whole plant does not, so this section carries more weight here than it does on a food page.

  • Interaction

    Inhibits drug-metabolising enzymes

    Interacts withCYP3A4, CYP2C9 and CYP2D6 substrates; warfarin

    Boswellic acids inhibit CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in laboratory work, and there is at least one clinical report of altered drug levels. Anyone on medication with a narrow therapeutic range should check before adding it.

  • Too much

    Gastrointestinal effects and reflux

    Nausea, acid reflux, abdominal pain and diarrhoea are the common complaints in trials. Taking it with food reduces them and also improves absorption.

  • Worth knowing

    The trial evidence belongs to specific patented extracts

    A generic capsule labelled "boswellia 500 mg" is not the material tested in the AKBA trials, which used enriched extracts with ten times the AKBA content. Milligrams on the front of the bottle do not indicate equivalence.

  • Avoid

    Avoid in pregnancy

    Boswellia preparations have traditionally been considered emmenagogic and there is no safety data in pregnancy or breastfeeding.

Evidence ratings on this page: 1 limited evidence, 2 not enough evidence.

Supplements are sold in the US without pre-market review of efficacy or safety. Nothing on this page is a recommendation to take Boswellic acid isolate (AKBA), or a dose to follow.